Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
Símbolo de cotizaciónAIMD
Nombre de la empresaAinos Inc
Fecha de salida a bolsaAug 08, 1996
Director ejecutivoMr. Chun-Hsien Tsai
Número de empleados44
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 08
Dirección8880 Rio San Diego Drive, Ste. 800
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92108
Teléfono18588692986
Sitio Webhttps://www.ainos.com/
Símbolo de cotizaciónAIMD
Fecha de salida a bolsaAug 08, 1996
Director ejecutivoMr. Chun-Hsien Tsai
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos